The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process
Open accessAbstract
Poly(ethylene glycol) (PEG) is receiving increasing attention as an intravenous therapeutic agent per se in a variety of experimental therapeutics and veterinary settings, such as spinal cord injury and traumatic axonal brain injury. PEG is often perceived to be immunologically safe, but here we demonstrate that near-monodisperse endotoxin-free PEGs, at concentrations relevant to above-mentioned settings, can generate complement activation products in human serum on a time scale of minutes (reflected in significant rises in serum levels of C4d, Bb, C3a-desArg and SC5b-9). With the aid of sera depleted from either C2 or C1q, and devoid of anti-PEG antibodies, we further demonstrate that, depending on PEG concentration and M(wt), generation of complement activation products occur either exclusively through the lectin pathway activation or through both the lectin pathway and increased fluid phase turnover of the alternative pathway. Inhibition of PEG-mediated C4d elevation in C1q-depleted serum by the broad serine protease inhibitor Futhan and anti-MASP-2 antibodies as well as competitive studies with d-mannose and N-acetylglucosamine indicated a likely role for ficolins/MASP-2 in PEG-mediated triggering of the lectin pathway and independent of calcium. PEG-mediated amplification of the alternative pathway is a complex process related to protein partitioning and exclusion effect, but factor H depletion/exclusion seems to play a minor role. Our results are relevant to the proposed potential therapeutic applications of intravenous PEG and warn about possible acute PEG infusion-related reactions in sensitive individuals and animals. PEG-mediated generation of complement activation products further provides a plausible explanation to the previously reported unexplained anaphylaxis or the referred cardiovascular collapse in sensitive animals that have received medicines containing high levels of PEG as solubilizer/carrier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441406 · Cited by 2,927
On Interaction between Two Bodies Immersed in a Solution of Macromolecules
Asakura, S., & Oosawa, F. (1954) · The Journal of Chemical Physics · doi:10.1063/1.1740347 · Cited by 2,914
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
Structure of a C-type mannose-binding protein complexed with an oligosaccharide
Weis, W. I., Drickamer, K., & Hendrickson, W. A. (1992) · Nature · doi:10.1038/360127a0 · Cited by 885
Yamaoka, T., Tabata, Y., & Ikada, Y. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830432 · Cited by 748
Complement evasion by human pathogens
Lambris, J. D., Ricklin, D., & Geisbrecht, B. V. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1824 · Cited by 722
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
Evolution of the lectin–complement pathway and its role in innate immunity
Fujita, T. (2002) · Nature Reviews Immunology · doi:10.1038/nri800 · Cited by 697
Pangburn, M. K., Schreiber, R. D., & Müller-Eberhard, H. J. (1977) · The Journal of experimental medicine · doi:10.1084/jem.146.1.257 · Cited by 684
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Self-citationHattori, R., Hamilton, K. K., McEver, R. P., & Sims, P. J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81901-9 · Cited by 438
Bhat, R., & Timasheff, S. N. (1992) · Protein Science · doi:10.1002/pro.5560010907 · Cited by 374
Poly(oxyethylene)−Water Interactions: A Molecular Dynamics Study
Tasaki, K. (1996) · Journal of the American Chemical Society · doi:10.1021/ja951005c · Cited by 366
Szebeni, J., Alving, C. R., & Muggia, F. M. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.4.300 · Cited by 341
Self-citationHuman C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator.
Fujita, T., Gigli, I., & Nussenzweig, V (1978) · The Journal of experimental medicine · doi:10.1084/jem.148.4.1044 · Cited by 284
Richter, A. W., & Åkerblom, E. (1983) · International Archives of Allergy and Immunology · doi:10.1159/000233309 · Cited by 282
Human C4-binding protein. I. Isolation and characterization
Scharfstein, J., Ferreira, A., Gigli, I., & Nussenzweig, V (1978) · The Journal of Experimental Medicine · doi:10.1084/jem.148.1.207 · Cited by 258
Tremper, K. K., Friedman, A. E., Levine, E. M., Lapin, R., & Camarillo, D. (1982) · New England Journal of Medicine · doi:10.1056/nejm198207293070503 · Cited by 244
Richter, A. W., & Åkerblom, E. (1984) · International Archives of Allergy and Immunology · doi:10.1159/000233512 · Cited by 229
L-ficolin Is a Pattern Recognition Molecule Specific for Acetyl Groups
Krarup, A., Thiel, S., Hansen, A., Fujita, T., & Jensenius, J. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407161200 · Cited by 203
Moein Moghimi, S., Hamad, I., Andresen, T. L., Jørgensen, K., Szebeni, J., Moein Moghimi, S., Hamad, I., Andresen, T. L., Jørgensen, K., & Szebeni, J. (2006) · The FASEB Journal · doi:10.1096/fj.06-6186fje · Cited by 201
Self-citationHamad, I. M., Hunter, A. C., Rutt, K. J., Liu, Z., Dai, H., & Moghimi, S. M. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.05.020 · Cited by 123
Self-citationBorgens, R. B., & Shi, R. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.1.27 · Cited by 121
Moghimi, S. M., Hunter, A. C., Dadswell, C., Sávay, S., Alving, C. R., & Szebeni, J. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.02.005 · Cited by 120
Self-citationSzebeni, J., Baranyi, L., Sávay, S., Bodó, M., Milosevits, J., Alving, C. R., & Bünger, R. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00622.2005 · Cited by 113
Self-citationRole of cardiac mast cells in complement C5a-induced myocardial ischemia
Ito, B. R., Engler, R. L., & del Balzo, U. (1993) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1993.264.5.h1346 · Cited by 55
Jack, D. L., Jarvis, G. A., Booth, C. L., TURNER, M. W., & Klein, N. J. (2001) · The Journal of Infectious Diseases · doi:10.1086/323204 · Cited by 54
Szebeni, J., Wassef, N. M., Spielberg, H., Rudolph, A. S., & Alving, C. R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2658 · Cited by 52
Self-citationKoob, A. O., & Borgens, R. B. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20837 · Cited by 49
Pulmonary complications after Fluosol administration to patients with life-threatening blood loss
Police, A. M., Waxman, K., & Tominaga, G. T. (1985) · Critical Care Medicine · doi:10.1097/00003246-198502000-00008 · Cited by 34
Conformational changes in the chains of polyoxyethyleneglycols
Kozielski, M. (2006) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2005.12.012 · Cited by 13
Cited by
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Owen, S. C., Chan, D. P. Y., & Shoichet, M. S. (2012) · Nano Today · doi:10.1016/j.nantod.2012.01.002 · Cited by 911
Design considerations for tumour-targeted nanoparticles
Choi, H. S., Liu, W., Liu, F., Nasr, K., Misra, P., Bawendi, M. G., & Frangioni, J. V. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2009.314 · Cited by 754
Metadata
- Authors
- Hamad, I., Hunter, A. C., Szebeni, J., & Moghimi, S. M.
- Venue
- Molecular Immunology
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 46
- Issue
- 2
- Pages
- 225-232
- ISSN
- 0161-5890 (ISSN-L)
- OpenAlex
- W2066404267
- Cited by
- 253
- References
- 32
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.